Medical-grade rubber tubing market poised to nearly double by 2035

Claymont, DE – The global medical-grade rubber tubing market is expected to nearly double in real terms by 2035 as demand grows for single-use equipment in biopharmaceutical manufacturing and flexible tubing used in medical devices, according to a new IndexBox report.

IndexBox projects the market to expand at a baseline compound annual growth rate of 7.2% from 2026 through 2035. Using 2025 as a base year with an index of 100, the market is forecast to reach 198 by 2035.

The growth is being driven in part by the shift from reusable equipment to single-use systems in biopharmaceutical production. Manufacturers of biologics, cell and gene therapies and other advanced medicines increasingly use disposable tubing assemblies in processing operations, raising tubing consumption with each production batch.

Biopharmaceutical manufacturing accounts for an estimated 35% of medical-grade rubber tubing demand, making it the largest end-use segment, IndexBox said. The segment is expected to grow 8% to 10% annually through 2035.

Hospitals and surgical care represent about 25% of demand, while diagnostics and laboratories account for roughly 20%. Patient monitoring and therapeutic devices make up another 15%, with the remainder coming from specialized applications such as veterinary care, dental equipment and research laboratories.

Silicone tubing currently represents an estimated 45% to 55% of global market volume. Thermoplastic elastomer, or TPE, products are gaining ground, with IndexBox estimating annual growth of 8% to 10% as manufacturers seek materials with lower extractables and broader chemical compatibility.

Demand is also increasing for tubing used in point-of-care diagnostics, wearable therapeutic devices and home health care. These applications require products that can withstand repeated flexing while maintaining biocompatibility and resistance to kinking.

Regulatory requirements are adding to manufacturers’ costs. IndexBox said stricter scrutiny of extractables and leachables, along with requirements under the European Union’s Medical Device Regulation and updated U.S. Pharmacopeia standards, is prompting companies to invest an estimated 15% to 25% more in material qualification for individual product lines.

Asia-Pacific is expected to lead global volume growth, supported by expanding health care infrastructure and increasing biopharmaceutical production in countries including China and India. The region is estimated to account for about 40% of the market.

North America represents roughly 30% of demand and is benefiting from investments in biologics, cell and gene therapies and single-use manufacturing. Europe accounts for about 20%, with demand supported by pharmaceutical production and stringent quality standards.

The market remains moderately concentrated, with the five to six largest globally certified producers estimated to account for 55% to 65% of compliant-grade tubing revenue. Companies compete not only on price but also on regulatory documentation, delivery times and the ability to produce customized tubing.

Among the companies identified by IndexBox as major participants are Saint-Gobain Performance Plastics, Freudenberg Medical, Tekni-Plex, W.L. Gore & Associates and Nordson MEDICAL.

The outlook is not without risks. Manufacturers face volatility in raw material costs, lengthy supplier-qualification cycles and rising regulatory expenses. IndexBox also cited the risk of counterfeit or non-compliant tubing entering distribution channels.

Still, the report forecasts continued expansion through 2035 as pharmaceutical manufacturers increase their use of single-use processing systems and health care shifts toward home-based, wearable and minimally invasive technologies.